{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:18:05Z","timestamp":1786997885629,"version":"build-2736575974"},"reference-count":41,"publisher":"Elsevier BV","issue":"28","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.vaccine.2012.03.002","type":"journal-article","created":{"date-parts":[[2012,3,16]],"date-time":"2012-03-16T19:57:50Z","timestamp":1331927870000},"page":"4276-4283","source":"Crossref","is-referenced-by-count":25,"title":["Human monoclonal antibodies generated following vaccination with AVA provide neutralization by blocking furin cleavage but not by preventing oligomerization"],"prefix":"10.1016","volume":"30","author":[{"given":"Kenneth","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry R.","family":"Crowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Garman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla J.","family":"Guthridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J.","family":"Muther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"McKee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai-Ying","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Darise","family":"Farris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel M.","family":"Guthridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick C.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith A.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2012.03.002_bib0005","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10254-004-0028-2","article-title":"Anthrax toxins","volume":"152","author":"Mourez","year":"2004","journal-title":"Rev Physiol Biochem Pharmacol"},{"key":"10.1016\/j.vaccine.2012.03.002_bib0010","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1128\/IAI.01145-10","article-title":"The poly-\u03b3-d-glutamic acid capsule of Bacillus anthracis enhances lethal toxin activity","volume":"79","author":"Jang","year":"2011","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2012.03.002_bib0015","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1146\/annurev.biochem.75.103004.142728","article-title":"Anthrax toxin: receptor binding, internalization, pore formation, and translocation","volume":"76","author":"Young","year":"2007","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.vaccine.2012.03.002_bib0020","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/385833a0","article-title":"Crystal structure of the anthrax toxin protective antigen","volume":"385","author":"Petosa","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2012.03.002_bib0025","doi-asserted-by":"crossref","first-page":"7049","DOI":"10.1073\/pnas.062160399","article-title":"Mapping the lethal factor and edema factor binding sites on oligomeric anthrax protective antigen","volume":"99","author":"Cunningham","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2012.03.002_bib0030","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.mam.2009.07.005","article-title":"Animal models of human anthrax: the quest for the Holy Grail","volume":"30","author":"Goossens","year":"2009","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.vaccine.2012.03.002_bib0035","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1001\/jama.300.13.1532","article-title":"Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial","volume":"300","author":"Marano","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2012.03.002_bib0040","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1086\/653495","article-title":"Select human anthrax protective antigen epitope-specific antibodies provide protection from lethal toxin challenge","volume":"202","author":"Crowe","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2012.03.002_bib0045","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.3390\/toxins3081004","article-title":"Monoclonal antibody therapies against anthrax","volume":"3","author":"Chen","year":"2011","journal-title":"Toxins"},{"key":"10.1016\/j.vaccine.2012.03.002_bib0050","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1128\/IAI.00261-07","article-title":"Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax","volume":"75","author":"Albrecht","year":"2007","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2012.03.002_bib0055","doi-asserted-by":"crossref","first-page":"6231","DOI":"10.1128\/IAI.70.11.6231-6241.2002","article-title":"Postexposure prophylaxis against anthrax: evaluation of various treatment regimens in intranasally infected guinea pigs","volume":"70","author":"Altboum","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2012.03.002_bib0060","doi-asserted-by":"crossref","first-page":"4859","DOI":"10.1128\/IAI.00117-09","article-title":"Neutralizing monoclonal antibodies directed against defined linear epitopes on domain 4 of anthrax protective antigen","volume":"77","author":"Kelly-Cirino","year":"2009","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2012.03.002_bib0065","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1006\/bbrc.1994.1281","article-title":"Structure-function analysis of Bacillus anthracis edema factor by using monoclonal antibodies","volume":"199","author":"Little","year":"1994","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.vaccine.2012.03.002_bib0070","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1128\/IAI.56.7.1807-1813.1988","article-title":"Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin","volume":"56","author":"Little","year":"1988","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2012.03.002_bib0075","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1128\/IAI.56.7.1807-1813.1988","article-title":"Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin","volume":"56","author":"Abboud","year":"1988","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2012.03.002_bib0080","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1574-695X.2006.00114.x","article-title":"Production and characterization of neutralizing monoclonal antibodies that recognize an epitope in domain 2 of Bacillus anthracis protective antigen","volume":"47","author":"Gubbins","year":"2006","journal-title":"FEMS Immunol Med Microbiol"},{"key":"10.1016\/j.vaccine.2012.03.002_bib0085","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1128\/IAI.73.2.795-802.2005","article-title":"A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge","volume":"73","author":"Mohamed","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2012.03.002_bib0090","doi-asserted-by":"crossref","first-page":"e6351","DOI":"10.1371\/journal.pone.0006351","article-title":"Isolation and chimerization of a highly neutralizing antibody conferring passive protection against lethal Bacillus anthracis infection","volume":"4","author":"Rosenfeld","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2012.03.002_bib0095","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1476-8518-2-5","article-title":"Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed","volume":"2","author":"Sawada-Hirai","year":"2004","journal-title":"J Immune Based Ther Vaccines"},{"key":"10.1016\/j.vaccine.2012.03.002_bib0100","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/nbt891","article-title":"Human antibodies from immunized donors are protective against anthrax toxin in vivo","volume":"21","author":"Wild","year":"2003","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.vaccine.2012.03.002_bib0105","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1086\/500148","article-title":"Efficient neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen","volume":"193","author":"Chen","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2012.03.002_bib0110","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1128\/IAI.00200-09","article-title":"Novel chimpanzee\/human monoclonal antibodies that neutralize anthrax lethal factor, and evidence for possible synergy with anti-protective antigen antibody","volume":"77","author":"Chen","year":"2009","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2012.03.002_bib0115","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1128\/IAI.01254-08","article-title":"Frequency and domain specificity of toxin-neutralizing paratopes in the human antibody response to anthrax vaccine adsorbed","volume":"77","author":"Reason","year":"2009","journal-title":"Infect Immun"},{"issue":"2","key":"10.1016\/j.vaccine.2012.03.002_bib0120","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1056\/NEJMoa0810603","article-title":"Raxibacumab for the treatment of inhalational anthrax","volume":"361","author":"Migone","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2012.03.002_bib0125","doi-asserted-by":"crossref","first-page":"11346","DOI":"10.1073\/pnas.172229899","article-title":"Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody","volume":"99","author":"Nowakowski","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2012.03.002_bib0130","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nature06890","article-title":"Rapid cloning of high-affinity human monoclonal antibodies against influenza virus","volume":"453","author":"Wrammert","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2012.03.002_bib0135","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/nprot.2009.3","article-title":"Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen","volume":"4","author":"Smith","year":"2009","journal-title":"Nat Protoc"},{"key":"10.1016\/j.vaccine.2012.03.002_bib0140","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1128\/IAI.72.6.3276-3283.2004","article-title":"Enhancement of anthrax lethal toxin cytotoxicity: a subset of monoclonal antibodies against protective antigen increases lethal toxin-mediated killing of murine macrophages","volume":"72","author":"Mohamed","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2012.03.002_bib0145","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1128\/IAI.00788-08","article-title":"Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies","volume":"77","author":"Nguyen","year":"2009","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2012.03.002_bib0150","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3233\/HAB-2004-13402","article-title":"Human monoclonal antibodies that neutralize anthrax toxin by inhibiting heptamer assembly","volume":"13","author":"Wang","year":"2004","journal-title":"Hum Antibodies"},{"key":"10.1016\/j.vaccine.2012.03.002_bib0155","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1128\/IAI.63.1.82-87.1995","article-title":"Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases","volume":"63","author":"Gordon","year":"1995","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2012.03.002_bib0160","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1128\/IAI.70.3.1653-1656.2002","article-title":"A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection","volume":"70","author":"Flick-Smith","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2012.03.002_bib0165","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1128\/CDLI.11.5.919-923.2004","article-title":"Mass value assignment of total and subclass immunoglobulin G in a human standard anthrax reference serum","volume":"11","author":"Semenova","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2012.03.002_bib0170","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jim.2008.01.007","article-title":"Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization","volume":"333","author":"Li","year":"2008","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2012.03.002_bib0175","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1128\/IAI.01722-07","article-title":"Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant","volume":"76","author":"Park","year":"2008","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2012.03.002_bib0180","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1128\/IAI.74.2.1009-1015.2006","article-title":"Cytokine response and survival of mice immunized with an adenovirus expressing Bacillus anthracis protective antigen domain 4","volume":"74","author":"McConnell","year":"2006","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2012.03.002_bib0185","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1128\/IAI.00358-09","article-title":"Synthetic peptide vaccine targeting a cryptic neutralizing epitope in domain 2 of Bacillus anthracis protective antigen","volume":"77","author":"Oscherwitz","year":"2009","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2012.03.002_bib0190","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.4049\/jimmunol.1001749","article-title":"A synthetic peptide vaccine directed against the 2\u03b22-2\u03b23 loop of domain 2 of protective antigen protects rabbits from inhalation anthrax","volume":"185","author":"Oscherwitz","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2012.03.002_bib0195","series-title":"The international conference on Bacillus anthracis, B. cereus & B. thuringiensis","first-page":"150","article-title":"Peptide epitope mapping of anthrax protective antigen using sera of rhesus macaques that survived inhalation anthrax","author":"Semenova","year":"2011"},{"key":"10.1016\/j.vaccine.2012.03.002_bib0200","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.4049\/jimmunol.170.7.3621","article-title":"More is not necessarily better: prozone-like effects in passive immunization with IgG","volume":"170","author":"Taborda","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2012.03.002_bib0205","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1128\/IAI.46.2.484-488.1984","article-title":"In vitro neutralization of Chlamydia trachomatis with monoclonal antibody to an epitope on the major outer membrane protein","volume":"46","author":"Peeling","year":"1984","journal-title":"Infect Immun"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12003477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12003477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,4]],"date-time":"2020-07-04T05:52:37Z","timestamp":1593841957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X12003477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":41,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0264410X12003477"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2012.03.002","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}